

## AMENDMENTS TO THE CLAIMS

This listing replaces all prior versions and listings of claims in the application.

### Listing of Claims

Please cancel claims 1-33 and add the claims indicated below.

1-33. Cancelled

34. (New) An isolated monoclonal antibody against ADAMTS-13, which antibody recognizes a portion of the polypeptide of the amino acid sequence constituting ADAMTS-13 of SEQ ID No. 1, wherein said portion is any of the disintegrin-like domain, the Tspl-1 domain or Cys-rich region to the spacer domain, the Tspl-2 domain, the Tspl-3 domain, the Tspl-4 domain, the Tspl-5 domain, the Tspl-6 domain, the Tspl-7 domain, and Tspl-8 domain.

35. (New) The isolated monoclonal antibody according to claim 34, which is an antibody produced by a hybridoma selected from the group consisting of hybridoma line WHIO (accession number FERM BP-8174), hybridoma line WH63.1 (accession number FERM BP-817S), hybridoma line WHS40.3 (accession number FERM BP-8176), hybridoma line Pep4H 34.1 (accession number FERM BP-8177), hybridoma line WH2-22-1A (accession number FERM BP-8483), hybridoma line WH2-1-1 (accession number FERM BP-8484), hybridoma line WH2-11-1 (accession number FERM BP-8485), hybridoma line Pep6-6A (accession number FERM BP-8474) and hybridoma line Pep4-SB-I (accession number FERM BP-847S).

36. (New) A pharmaceutical composition comprising a monoclonal antibody according to claim 35.

37. (New) A hybridoma that is selected from the group consisting of hybridoma line WHIO (accession number FERM BP-8174), hybridoma line WH63.1 (accession number FERM BP-8175), hybridoma line WHS40.3 (accession number FERM BP-8176), hybridoma line Pep4-34.1 (accession number FERM BP-8177), hybridoma line WH2-22-1A (accession number FERM BP-8483), hybridoma line WH2-1-1 (accession number FERM BP-8484), hybridoma line WH2-11-1 (accession number FERM BP-848S), hybridoma line Pep6-6A (accession number FERM BP-8474) and hybridoma line Pep4-5B-I (accession number FERM BP-8475).

38. (New) An immunoassay kit comprising an antibody according to claim 35.

39. (New) A method for detecting ADAMTS-13, comprising contacting a monoclonal antibody according to claim 35 with an analysis target and then detecting ADAMTS-13 by immunoreaction.

40. (New) The detection method according to claim 39, which is carried out by radioimmunoassay, enzyme immunoassay or fluoroimmunoassay using said antibody.

41. (New) The detection method according to claims 39, wherein the analysis target is a biological sample extracted from a living body.

42. (New) The detection method according to claims 40, wherein the analysis target is a biological sample extracted from a living body.

43. (New) A process for purifying ADAMTS-13, comprising (A) contacting a monoclonal antibody according to claim 35 with a mixture containing ADAMTS-13 and impurities, to adsorb said protein on the antibody, and then (B) desorbing said adsorbed protein from the antibody.

44. (New) The purification method according to claim 43, wherein the antibody is bound to a water-insoluble carrier.